Publications

• Evaluation of Proclarix in the diagnostic work-up of prostate cancer


• Relationship between Proclarix and the Aggressiveness of Prostate Cancer


• Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging


• New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.


• Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI


• Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?


• Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category


• The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer


• A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology


• PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer


• Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer


• Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer


• Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer


• Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies


• Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer


• A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: findings of a recent study


• A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: findings of a recent study


• Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)


• Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)


• N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications


• Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)


• Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome


• On the development of plasma protein biomarkers


• Biomarker validation in blood specimens by selected reaction monitoring mass spectrometry of N-glycosites


• Targeted proteomic strategy for clinical biomarker discovery
   
• Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
   
• Thompson, C. P., Lourenço, J., Walters, A. A., Obolski, U., Edmans, M., Palmer, D. S., Kooblall, K., Carnell, G. W., O'Connor, D., Bowden, T. A., Pybus, O. G., Pollard, A. J., Temperton, N. J., Lambe, T., Gilbert, S. C., & Gupta, S. (2018). A naturally protective epitope of limited variability as an influenza vaccine target. Nature communications, 9(1), 3859.
  https://doi.org/10.1038/s41467-018-06228-8


• Rosch, J. W., Iverson, A. R., Humann, J., Mann, B., Gao, G., Vogel, P., Mina, M., Murrah, K. A., Perez, A. C., Edward Swords, W., Tuomanen, E. I., & McCullers, J. A. (2014). A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO molecular medicine, 6(1), 141–154.
  https://doi.org/10.1002/emmm.201202150


• Ramesh, A., Mao, J., Lei, S., Twitchell, E., Shiraz, A., Jiang, X., Tan, M., & Yuan, A. L. (2019). Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs. Vaccines, 7(4), 177.
  https://doi.org/10.3390/vaccines7040177